Doctors have for the first time in the United States tested a powerful gene-editing technique in people with cancer.
Thanks to the complete sequencing of the human genome, scientists are now able to understand the functioning of our body and what could cause a particular disease. In the near future biotechnology related to human health, agriculture and the environment, will create a global market in the order of several hundreds of billions of dollars. In healthcare, new biotechnology drugs sales already exceed USD 130 billion and in the top ten best-selling drugs in the world as many as six derived from biotechnology companies. We are living in the era of biotechnology!
Doctors have for the first time in the United States tested a powerful gene-editing technique in people with cancer.
In the earnings call yesterday after the close, Nektar Therapeutics (NASDAQ:NKTR) President & CEO Howard Robin mentioned a "softening in response rates" in the Phase 1/2 PIVOT-02 study evaluating NKTR-214 (bempegaldesleukin)
The FDA approves Incyte's Jakafi (ruxolitinib) for the treatment of steroid-refractory acute graft-versus-host disease (GvHD)
Copyright © 2023 | J. LAMARCK S.P.A. Powered by Moving